Carlisle Cos. (CSL) –
-
Carlisle (CSL) PT Raised to $412 at Oppenheimer
-
Carlisle Companies to Announce First Quarter 2024 Results on April 25, 2024
-
Armstrong World Industries Names Dawn Kirchner-King as SVP, Chief Human Resources Officer
-
Form 8-K CARLISLE COMPANIES INC For: Apr 03
-
Goldman Sachs Starts Carlisle (CSL) at Buy, 'Emerging Re-Roof Cycle Furthered by Company-Specific Initiatives'
-
Carlisle (CSL) PT Raised to $440 at Loop Capital
-
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
-
Carlisle (CSL) PT Raised to $405 at Oppenheimer
-
Form 8-K CARLISLE COMPANIES INC For: Mar 18
-
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
-
Carlisle (CSL) PT Raised to $400 at Baird
-
Form ARS CARLISLE COMPANIES INC For: Dec 31
-
Form DEFA14A CARLISLE COMPANIES INC
-
Form DEF 14A CARLISLE COMPANIES INC For: May 01
-
Carlisle Cos. (CSL) to Acquire MTL Holdings
-
Carlisle Companies to Acquire MTL Holdings, a Leader in Edge Metal and Non-Insulated Architectural Wall Systems
-
Carlisle Cos. (CSL) Files Mixed Shelf
-
Form S-3ASR CARLISLE COMPANIES INC
-
Form SC 13G/A CARLISLE COMPANIES INC Filed by: BlackRock Inc.
-
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
-
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: OSTRANDER GREGG A
-
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Singh Jesse G
-
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Ricard Corrine D.
-
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: BOHN ROBERT G
-
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: ADAMS ROBIN J
-
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Collins Jonathan R.
-
Form 4 CARLISLE COMPANIES INC For: Mar 01 Filed by: Frias James D
-
Form PRE 14A CARLISLE COMPANIES INC For: May 01
-
Travere Therapeutics (TVTX) and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
-
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
-
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
-
Form 4 CARLISLE COMPANIES INC For: Feb 21 Filed by: KOCH D CHRISTIAN
-
Form 4 CARLISLE COMPANIES INC For: Feb 15 Filed by: KOCH D CHRISTIAN
-
Form 10-K CARLISLE COMPANIES INC For: Dec 31
-
Form SC 13G/A CARLISLE COMPANIES INC Filed by: VANGUARD GROUP INC
-
Form 144 CARLISLE COMPANIES INC Filed by: KOCH D CHRISTIAN
-
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
-
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Snyder Lori A
-
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Schwar Stephen
-
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: SMITH DAVID W
-
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Selbach Scott C
-
Form 4 CARLISLE COMPANIES INC For: Feb 08 Filed by: Berlin John E
-
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
-
Form 144 CARLISLE COMPANIES INC Filed by: Snyder Lori A
-
Form 144 CARLISLE COMPANIES INC Filed by: Snyder Lori A
-
Form 144 CARLISLE COMPANIES INC Filed by: Schwar Stephen
-
Form 144 CARLISLE COMPANIES INC Filed by: Berlin John E
-
Form 144 CARLISLE COMPANIES INC Filed by: SMITH DAVID W
-
Form 144 CARLISLE COMPANIES INC Filed by: Selbach Scott C
-
Carlisle (CSL) PT Raised to $355 at Oppenheimer
Back to CSL Stock Lookup
